ClinicalTrials.gg
WithdrawnNCT01512095Updated Sep 16, 2013

Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers

A Phase 1 interventional study of somatropin and somatropin in Growth Disorder and Healthy, sponsored by Novo Nordisk A/S. Withdrawn. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-09-16.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This trial is conducted in Europe and United States of America (USA). The aim of this trial is to examine the bioequivalence (assessment of the expected biological equivalence of two pharmaceutical drug products with identical active ingredient) of Norditropin® versus Nutropin AQ® in healthy adult volunteers.

02

Conditions studied

  • Growth Disorder
  • Healthy

Browse trials for

03

In context

Growth Disorders

227 studies on the registry are indexed under Growth Disorders; 25 are open to participants now.

Browse Growth Disorders studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No previous exposure to recombinant human GH (growth hormone)or IGF-I (insulin-like growth factor-I)
  • (BMI) 18.0-27.0 kg/m\^2 (both inclusive)
  • Considered generally healthy upon completion of medical history, physical examination, vital signs, screening laboratory results, and (ECG), as judged by the Investigator

Exclusion criteria

Exclusion Criteria:

  • The receipt of any medicinal product within 1 month prior to this trial
  • Current or previous treatment with recombinant human growth hormone or IGF-I
  • Female of who is pregnant, breast-feeding or intends to become pregnant or is not using adequate methods (adequate contraceptive measures as required by local law) for the duration of the trial
  • Known presence or history of
  • Diabetes mellitus
  • Use of pharmacologic doses of
  • Use of anabolic steroids
  • History of drug or alcohol abuse
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Norditropin®

    Drug: somatropin

  • Active comparator
    Nutropin AQ®

    Drug: somatropin

Interventions

  • A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period

  • A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period

06

What researchers measure

Primary outcomes

  1. Area under the serum hGH (human growth hormone) concentration-time curve (AUC0-t)

    Time frame: From 0 to the time of the last quantifiable concentration over a 24-hour sampling period

  2. Maximum observed serum hGH concentration

    Time frame: Over a 24-hour sampling period

  3. Area under the effect (IGF-I) curve from time 0 to the time of the last concentration (AUEC0-t)

    Time frame: Over a 96-hour sampling period

  4. Maximum IGF-I (insulin-like growth factor-I) effect (Emax)

    Time frame: Over a 96-hour sampling period

Secondary outcomes

  1. The frequency of adverse events (AE) and vital signs

    Time frame: From screening (14 days before randomisation) to follow-up period (3-21 days after randomisation)

  2. The frequency of abnormal hematology

    Time frame: From screening (14 days before randomisation) to follow-up period (20-23 days after randomisation)

  3. The frequency of abnormal findings in physical examinations

    Time frame: From screening (14 days before randomisation) to follow-up period (20-23 days after randomisation)

  4. Biochemistry laboratory parameters

    Time frame: From screening (14 days before randomisation) to follow-up period (20-23 days after randomisation)

  5. The frequency of injection site reaction

    Time frame: From the time of injection of the trial product (day 1 and day 13) to follow-up during the two dosing periods (day 5 and day 17)

  6. Area under the effect (IGFBP-3) curve

    Time frame: From time 0 to the time of the last concentration (AUEC0-t) over a 96-hour sampling period

  7. Maximum IGFBP-3 (insulin-like growth factor binding protein 3) effect (Emax)

    Time frame: Over a 96-hour sampling period

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2012
First posted
Jan 19, 2012
Start
Aug 2013
Primary completionEst.
Nov 2013
CompletionEst.
Nov 2013
Last update
Sep 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01512095
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 19, 2012
Start date
Aug 2013
Primary completion
Nov 2013 (estimated)
Completion
Nov 2013 (estimated)
Last update
Sep 16, 2013

Study contacts

John Germak
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion